Blog

New dosing options for PD-1 inhibitor in first and second-line esophageal squamous cell carcinoma – BeOne Medicines

BeOne Medicines/Instagram

Apr 24, 2025, 11:06

New dosing options for PD-1 inhibitor in first and second-line esophageal squamous cell carcinoma – BeOne Medicines

BeOne Medicines shared a post on LinkedIn:

“The FDA has approved new dosing options for our PD-1 inhibitor in both first- and second-line esophageal squamous cell carcinoma (ESCC) and first-line gastric cancer, providing more flexibility for pairing our immunotherapy with the most common chemotherapy regimens.

This approval reinforces our dedication to patients in the U.S. living with upper GI cancers—helping to expand access to personalized treatment approaches and supporting providers in delivering care that fits the unique needs of each patient.”

New dosing options for PD-1 inhibitor in first and second-line esophageal squamous cell carcinoma - BeOne Medicines

BeOne Medicines cancer chemotherapy ESCC esophageal squamous cell carcinoma FDA fight against cancer GI cancers Global fight against cancer immunotherapy OncoDaily Oncology PD-1 inhibitor

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection

Who From Oncology is Featured in TIME100 Health 2025?

FDA Announces Aggressive Timeline to Scale 1st AI-Assisted Scientific Review Pilot